AI & Technical question
Production monitoring shows a model improves average note quality but increases rare critical errors. How would you investigate whether this is a measurement artifact, a distribution shift, or a real safety regression, and how would you decide between shipping, pausing, rolling back, or narrowing scope?
- Abridge
- AI & Technical
- Hard
Practice this question out loud. An AI interviewer asks it, follows up like a real interviewer would, and scores your answer. Type or speak.
Start a mock interview on this question · Mock interview from a job description
What this question tests
Tests root cause diagnosis for a model regression and the judgment to choose between shipping, pausing, or rolling back under ambiguity.
How to approach it
- Check whether the critical error definition or eval set changed alongside the model, which would make this a measurement artifact.
- Slice the critical errors by patient population, note type, and clinician to see if the increase is a real distribution shift.
- Compare the absolute number of critical errors, not just the rate, since average quality gains can mask a small but serious tail.
- Pull the actual critical error transcripts and have clinical reviewers confirm they are true safety issues, not scoring noise.
- Decide based on severity and reversibility: pause or roll back if errors are clinically dangerous and hard to detect downstream, ship with narrowed scope otherwise.
What a strong answer includes
- Insists on human clinical review of the actual failing cases before trusting an aggregate error rate.
- Weighs asymmetric cost: a rare critical error in a clinical note can be far worse than a small quality dip, so bar for shipping is higher.
- Considers narrowing scope, for example excluding the note types where errors cluster, as a middle option between ship and roll back.
Common mistakes
- Treating average quality improvement as sufficient justification to ship without inspecting the tail.
- Rolling back without first confirming whether the increase is a real regression or an artifact of a changed eval.
Likely follow-up questions
- How would you distinguish a distribution shift from a genuine model regression?
- What monitoring would you put in place to catch this kind of rare error earlier next time?
More ai & technical questions
- Abridge has a post-training approach that uses clinician edits, final notes, and EHR context to improve note generation. How would you define the hypotheses, stage gates, and success metrics to take it from offline research to shadow mode to a limited production launch? What evidence would be required at each step to continue, pause, or kill the effort?Abridge · AI & Technical · Hard
- For a model that turns patient-clinician conversations into structured clinical notes, what evaluation suite would you use beyond aggregate quality scores? Specify the failure modes you would prioritize, how you would segment risk by workflow or note type, and the thresholds or escalation paths you would require before declaring the model safe enough to scale.Abridge · AI & Technical · Hard
- Abridge has access to de-identified conversations, clinician edits, final signed notes, EHR context, and downstream care actions, but each signal differs in coverage, cost, bias, and clinical relevance. How would you prioritize which signals to use first for post-training, and what framework would you use to decide whether a sparse, subjective, or expensive signal is still worth operationalizing?Abridge · AI & Technical · Hard
- A chart-aware CDS assistant must feel fast enough for live clinical use while staying reliable and evidence-grounded. How would you work with engineering and ML to define the system tradeoffs and product requirements around latency, retrieval quality, grounding, fallback behavior, and failure handling, and what technical or model-level changes would you prioritize first if response time improved only by reducing answer quality?Abridge · AI & Technical · Hard
- Abridge has a new AI-assisted clinician workflow whose model quality is improving but still imperfect. What launch criteria would you set before exposing it in live care, how would you combine offline evals, human review, and UX guardrails, and how would you phase the rollout to manage clinical and compliance risk?Abridge · AI & Technical · Hard
- Abridge explicitly uses LLM judges, rule-based evaluators, human annotation, and online monitoring. How would you decide which of these methods belongs at each stage of the eval lifecycle, and what failure modes, cost/speed tradeoffs, and confidence limits would you communicate before teams rely on them for launch decisions?Abridge · AI & Technical · Hard
More questions from Abridge
Learn the skill behind it
Chapters of the AI PM course that teach what this question tests.
- Chapter 1: Foundations: the model and the decisions it forces on you
- Chapter 8: Evals: define good and make the number defensible
- Chapter 6: Agents and agentic architecture